Stay updated with breaking news from Similis Bio. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Takeda published the results of Ph III trials of vedolizumab in the prevention of intestinal acute graft-versus-host disease (aGvHD) in patients…
JSR Life Sciences, LLC ("JSR") today announced that Similis Bio ("Similis"), its business unit focused on biosimilar development, has announced plans to enter into a partnership with Novel351k to co-develop
On October 25, 2022, JSR Life Sciences and Blau Farmaceutica announced that Similis Bio, JSR Life Sciences's business unit focused on biosimilar development, has signed its first development and license agreement...
On October 25, 2022, JSR Life Sciences and Blau Farmaceutica announced that Similis Bio, JSR Life Sciences’s business unit focused on biosimilar development, has signed its first...
JSR Life Sciences, LLC (JSR) and Blau Farmaceutica (Blau) (public company in Brazil B3 – BLAU3) today announced that Similis Bio (“Similis”), its recently launched business unit focused on biosimilar development, has signed its first development and license agreement with Blau Farmacêutica (“Blau”). The agreement ...